University of Oulu

Lindgren, O., Varpuluoma, O., Tuusa, J., Ilonen, J., Huilaja, L., Kokkonen, N., Tasanen, K. (2019) Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid, 99 (6), 602-609. doi:10.2340/00015555-3166

Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4/CD26 in bullous pemphigoid

Saved in:
Author: Lindgren, Outi1; Varpuluoma, Outi2; Tuusa, Jussi2;
Organizations: 1Department of Pathology, MRC Oulu, University of Oulu and Oulu University Hospital
2Department of Dermatology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu
3Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku and Clinical Microbiology, Turku University Hospital, Turku, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 1.6 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe202003279477
Language: English
Published: Society for Publication of Acta Dermato-Venereologica, 2019
Publish Date: 2020-03-27
Description:

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP-4i or gliptins) increase the risk of developing bullous pemphigoid (BP). To clarify, whether gliptin-associated BP has special features, we analyzed the clinical, histopathological and immunological features of 27 BP patients, 10 of which previously used gliptin medication. Compared to those who had not previously received gliptins, subjects who had, showed higher BP180-NC16A ELISA (enzyme-linked immunosorbent assay) values, fewer neurological co-morbidities and shorter time to remission, but differences were not statistically significant. The HLA-DQB1*03:01 allele was more commonly present among the BP patients than the control population, but was not more common in those with gliptin history. To determine the effect of gliptins on the expression of the DPP-4/CD-26 protein we performed immunohistochemistry, which showed that the skin expression of DPP-4/CD-26 was increased in BP patients, but not affected by prior gliptin treatment. We conclude that DPP-4i medication is common among BP patients and prior gliptin treatment may be associated with some specific features.

see all

Series: Acta dermato-venereologica
ISSN: 0001-5555
ISSN-E: 1651-2057
ISSN-L: 0001-5555
Volume: 99
Issue: 6
Pages: 602 - 609
DOI: 10.2340/00015555-3166
OADOI: https://oadoi.org/10.2340/00015555-3166
Type of Publication: A1 Journal article – refereed
Field of Science: 3121 General medicine, internal medicine and other clinical medicine
Subjects:
Funding: This study was supported by the Academy of Finland, Medical Research Center Oulu and the Sigrid Juselius Foundation.
Copyright information: This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta. Journal Compilation © 2019 Acta Dermato-Venereologica.
  https://creativecommons.org/licenses/by-nc/4.0/